We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 106% below its sector, cheaper than its peers on earnings.
Based in Melbourne, Australia, Patrys Limited and its subsidiaries specialize in developing and commercializing advanced antibody technologies for cancer treatment. Their leading therapeutic, Deoxymab 3E10, is a distinctive DNA damage-repair antibody capable of penetrating cell nuclei. The company's pipeline also includes PAT-DX1, an antibody fragment specifically designed to target both primary and secondary brain cancers. Furthermore, Patrys is progressing PAT-DX3, a full-sized antibody that shares PAT-DX1's DNA-binding and DNA damage repair blocking properties, currently being evaluated for its tissue distribution and pharmacokinetic profile. Another promising development is PAT-DX1-NP, a product leveraging the targeted delivery of therapeutic payload-carrying nanoparticles directly into cancer cells. Patrys Limited was established in 2006.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save PAB.AX and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
